CN102495217B - Clinical case monitoring and managing system - Google Patents
Clinical case monitoring and managing system Download PDFInfo
- Publication number
- CN102495217B CN102495217B CN201110399730.XA CN201110399730A CN102495217B CN 102495217 B CN102495217 B CN 102495217B CN 201110399730 A CN201110399730 A CN 201110399730A CN 102495217 B CN102495217 B CN 102495217B
- Authority
- CN
- China
- Prior art keywords
- glycosylated hemoglobin
- container
- magnetic bead
- solution
- mentioned
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012544 monitoring process Methods 0.000 title claims abstract description 20
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims abstract description 37
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims abstract description 37
- 210000004369 blood Anatomy 0.000 claims abstract description 21
- 239000008280 blood Substances 0.000 claims abstract description 21
- 238000001514 detection method Methods 0.000 claims abstract description 9
- 239000011324 bead Substances 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000008213 purified water Substances 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000013016 damping Methods 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 11
- 238000007885 magnetic separation Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000007983 Tris buffer Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 239000012744 reinforcing agent Substances 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- 238000010241 blood sampling Methods 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 150000001718 carbodiimides Chemical class 0.000 claims description 6
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 5
- 108010054147 Hemoglobins Proteins 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000001186 cumulative effect Effects 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 235000000346 sugar Nutrition 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Abstract
The invention discloses a clinical case monitoring and managing system, and particularly relates to a clinical case monitoring and managing system for the II-type diabetes. The monitoring and managing system comprises a blood collection device and a glycosylated hemoglobin detection device. The invention also discloses a method for preparing the monitoring and managing system. The clinical case monitoring and managing system for the II-type diabetes can be used for detecting a glycosylated hemoglobin index of a diabetes patient simply and effectively so as to monitor the recovery condition of the patient and adjust the medicine dosage.
Description
Technical field
The present invention relates to a kind of clinical case management system for monitoring, especially relate to a kind of type ii diabetes clinical case management system for monitoring.
Background technology
Diabetes (diabetes) are by inherent cause, immunologic function disorder, infected by microbes and toxin thereof, free radical toxin, the various virulence factors of mental element etc. act on body and cause hypoinsulinism, insulin resistance etc. and cause sugar, protein, fat, a series of metabolic disorder syndromes such as power and water Xie Zhi, clinically take hyperglycaemia as principal feature, can there is diuresis in model case, many drinks, many foods, the performance such as become thin, i.e. " three-many-one-little " symptom, diabetes (blood sugar) cause complication once control bad meeting, cause kidney, eye, the exhaustion pathology at the positions such as foot, and cannot cure.Clinical observation insulin resistance is prevalent in type ii diabetes, up to 90% left and right.Type ii diabetes can cause infection, heart change, cerebrovascular disease, renal failure, loses the sight of both eyes, lower limb gangrene etc. and become the lethal main cause disabling.Diabetes are high oozes the serious acute complication that syndrome is diabetes, starting stage can show as diuresis, many drinks, lassitude hypodynamia, slow in reacting etc., along with the increase state of an illness of body fluid loss sharply develops, occur that drowsiness, disorientation, epileptic twitch, the symptom of the similar cerebral apoplexy such as hemiplegia, even stupor.
Glycosylated hemoglobin is the product that in blood of human body, endoerythrocytic haemoglobin is combined with blood sugar.Glycosylated hemoglobin was used chromatography from the haemoglobin of other type, to separate first in 1958, and was classified as a kind of glycoprotein in nineteen sixty-eight.1969, it is found that the quantity of glycosylated hemoglobin in diabetic increases.Researchers in 1975 have obtained generating the reaction equation of glycosylated hemoglobin.The product that in blood of human body, endoerythrocytic haemoglobin is combined with blood sugar is glycosylated hemoglobin, it is non-reversible reaction that the combination of blood sugar and haemoglobin generates glycosylated hemoglobin, and be directly proportional to blood sugar concentration, glycosylated hemoglobin can more fully reflect type ii diabetes patient's glycemic control situation.In blood of human body, endoerythrocytic haemoglobin is easily combined with blood sugar, in conjunction with product be exactly glycosylated hemoglobin.This combination is an irreversible process substantially, once in conjunction with being just difficult to dissociate.Erythrocytic life cycle is 120 days, only has red blood cell decline by the time, and this combination just can stop.Certainly, red blood cell is constantly survived, also constantly dead.So the glycosylated hemoglobin value detecting has clinically reflected the blood sugar average level of the nearest 2-3 of patient month, is not subject to for a single second impact of blood glucose fluctuation, more objective, has more longer timeliness, is also still less subject to the interference of the factor such as diet, motion.
At present the index of reaction type ii diabetes blood sugar have multiple, as the fasting blood-glucose of direct reflection blood sugar level, 2 hours blood glucoses etc. after the meal.Although these indexs can reflect blood sugar level, clinical meaning or different.By fasting blood-glucose, we can understand the general status of patient's glycemic control.Fasting blood-glucose is high, means patient's Basal insulin secretion ability.Postprandial blood sugar is high, often points out the reserve capabillity of excreting insulin poor or have an insulin resistance.The monitoring of how carrying out type ii diabetes patient according to glycosylated hemoglobin index has become a medically difficult problem with standardization medication.
Summary of the invention
The technical issues that need to address of the present invention are the present invention relates to a kind of diabetes clinical case management system for monitoring, especially relate to a kind of type ii diabetes clinical case management system for monitoring, the kit that this system adopts the present invention to develop carries out glycosylated hemoglobin detection and has higher sensitivity and specificity, can be used for instructing clinical type ii diabetes clinical.
Type ii diabetes clinical case management system for monitoring provided by the invention, comprises blood sampling device and glycosylated hemoglobin pick-up unit, and described blood sampling device can be any conventional blood sampling device of field of medicaments, such as venous detaining needle, syringe and blood collecting pen etc.Described glycosylated hemoglobin pick-up unit is glycosylated hemoglobin detection kit, and its reagent comprising has glycosylated hemoglobin magnetic separation agent, enzyme labelled antibody, reinforcing agent, calibration object, control product, concentrate and substrate.
Described magnetic separation agent contains the magnetic microsphere that is marked with anti-glycosylated hemoglobin monoclonal antibody.
Described enzyme labelled antibody is the anti-glycosylated hemoglobin monoclonal antibody that contains horseradish peroxidase-labeled.
Described reinforcing agent is the damping fluid that contains Tris.
Described calibration object and control product are the solution that contains a certain amount of glycosylated hemoglobin antigen.
Described concentrate is the damping fluid that contains TWEEN-20 and Proclin-300.
Described substrate is enzyme-catalyzed chemical luminescence substrate.
The preparation method of the immue quantitative detection reagent box of glycosylated hemoglobin of the present invention, comprises the steps:
The first step: the preparation process of magnetic separation agent:
1,1.0mg disuccinimidyl suberate is dissolved in 50ul DMSO, get in the 0.1mol/L PB damping fluid that the anti-glycosylated hemoglobin monoclonal antibody of 2mg is dissolved in PH 9.5 to cumulative volume be 1ml;
2, join in the antibody-solutions of step 1 with the disuccinimidyl suberate that liquid-transfering gun is drawn in step 1, put room temperature 90min;
3, solution step 2 being obtained join in concentration tube, then put in high speed freezing centrifuge under 3000g concentrated 30min to volume be 0.5ml;
4, get 0.5ml magnetic bead, add in 5ml reaction cup, put into test tube rack special, after 2 minutes, draw supernatant through magnet adsorption;
5, add 1.5ml PH9.50.1mol/L PB at every turn, mix 30 seconds, added, remove supernatant, repetitive operation 3 times; The antibody-solutions that step 3 is obtained joins in above-mentioned magnetic bead, mixes rear room temperature reaction 4 hours;
6, add 37 ℃ of the TRIS solution 15 minutes of 0.3ml 1mol/L;
7, add 1.5ml PH 7.20.1mol/L PB to clean the magnetic bead of mark at every turn, mix 30 seconds, added, remove supernatant, repetitive operation 3 times;
8, preserve liquid with 100ml magnetic bead magnetic bead is proceeded to 125ml vial; It is 0.1%BSA that magnetic bead is preserved formula of liquid (mass volume ratio), 0.05% Tween-20,0.02%NaN3,20% ethanol, 4 ℃ of preservations.
9, magnetic separation agent magnetic bead buffer solution step 8 being obtained mixes according to the volume ratio of 1: 1, obtains magnetic separation agent in kit of the present invention; Described magnetic bead buffer solution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
Second step: enzyme labelled antibody preparation process:
1,2.5mg glycosylated hemoglobin monoclonal antibody is dissolved in the N of 1.0ml, in dinethylformamide, add 10mg/ml horseradish peroxidase aqueous solution and the 1.3mg carbodiimides of 1ml, after 1 hour, the carbodiimides of 1.0ml 20mg/ml is added, potpourri constantly stirs, and 4 ℃ are spent the night;
2, the solution of step 1 is packed in bag filter, to the PH7.4PBS dialysis of 0.15M, 4 ℃ are spent the night, and collect and retain liquid; Then adding 10ml concentration is the BSA solution of 15mg/ml, and 4 ℃ store for future use; Finally the horseradish peroxidase of collecting is mixed with the volume ratio of 1: 1000 with enzyme labelled antibody dilution with the conjugate of glycosylated hemoglobin monoclonal antibody, obtain enzyme labelled antibody; Described enzyme labelled antibody dilution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
The 3rd step: reinforcing agent preparation steps:
1, take TRIS1.56g and NaCl 4.23g in 1L container; With pipettor by Proclin-300 measure 0.2ml in the beaker of 10ml purified water completely dissolve after, pour in above-mentioned 1L container;
2, measure 800ml purified water in above-mentioned 1L container with graduated cylinder, fully stir, adjust PH until dissolve completely, control PH between 7.35-7.45;
3, take Mak330.9g in above-mentioned 1L container; Last constant volume 1000ml, after dissolving completely, with the filtration of 0.2um filter.
The 4th step:
The preparation of calibration object and the product of control:
Calibration object concentration is respectively 50,100,200,400,800ng/ml; Control product concentration is respectively 100,400ng/ml.
The 5th step:
Cleaning concentrate preparation steps, preparation 1L:
1, take TRIS 12.54g and NaCl 325.6g in 1L container;
2, after taking 5g Tween-20 and adding 20ml water in 100ml container it is dissolved completely, pour in above-mentioned 1L container;
3, with pipettor by Proclin-300 measure 0.2ml in the beaker that fills 10ml purified water completely dissolve after, pour in above-mentioned 1L container;
4, measure 800ml purified water in above-mentioned 1L container with graduated cylinder, fully stir, until dissolve completely;
5, adjust PH, control its scope between 7.35-7.45;
6, last constant volume 1000ml, filters and get final product with 0.2um filter after dissolving completely.
The 6th step:
Substrate preparation steps, preparation 1L:
1, take TRIS 2.35g, NaCl 6.41g, Na
2sO
30.002g and Proclin-3000.2ml are in 1L beaker;
2, measure 600ml purified water in 1L beaker with graduated cylinder, fully stir, until dissolve completely, adjust PH, control its scope between 7.95-8.05;
3, add after 250ml Lumi-Phos 530, filter and collect filtrate with 0.2um filter, be settled to 1000ml by purified water, after mixing and get final product.
Main innovation part of the present invention is:
Type ii diabetes clinical case management system for monitoring of the present invention can detect diabetic's glycosylated hemoglobin index simply and effectively, thus monitoring patient's recovery situation, and regulate medication.
Management system for monitoring of the present invention kit used combines chemiluminescence with immune magnetic particle, a kind of reaction system that approaches homogeneous phase is provided, compared with prior art, kit preparation technology simple possible of the present invention, there is higher detection sensitivity and specificity, experimental result is effectively stable, and has reached preferably performance parameter.
Embodiment
Embodiment 1,
One, the preparation process of magnetic separation agent:
1,1.0mg disuccinimidyl suberate is dissolved in 50ul DMSO, get in the 0.1mol/L PB damping fluid that 2mg glycosylated hemoglobin monoclonal antibody (Santa Cruz company product) is dissolved in PH 9.5 to cumulative volume be 1ml;
2, join in the antibody-solutions of step 1 with the disuccinimidyl suberate that liquid-transfering gun is drawn in step 1, put room temperature 90min;
3, the solution of step 2 is joined in Centricon-10 concentration tube, then put in high speed freezing centrifuge under 3000g concentrated 30min to volume be 0.5ml;
4, get 0.5ml magnetic bead, add in 5ml reaction cup, put into test tube rack special, after 2 minutes, draw supernatant through magnet adsorption;
Magnetic bead is the conventional magnetic bead in this area, preferred concentration 25mg/mL, and diameter is 800nm.
5, add 1.5ml PH9.50.1mol/L PB at every turn, mix 30 seconds, added, remove supernatant, repetitive operation 3 times; The antibody-solutions that step 3 is obtained joins in above-mentioned magnetic bead, mixes rear room temperature reaction 4 hours;
6, add 37 ℃ of the TRIS solution 15 minutes of 0.3ml 1mol/L;
7, add 1.5ml PH 7.20.1mol/L PB to clean the magnetic bead of mark at every turn, mix 30 seconds, added, remove supernatant, repetitive operation 3 times;
8, preserve liquid with 100ml magnetic bead magnetic bead is proceeded to 125ml vial; It is 0.1%BSA that magnetic bead is preserved formula of liquid (being mass volume ratio), 0.05% Tween-20,0.02%NaN3,20% ethanol, 4 ℃ of preservations.
9, solution step 8 being obtained mixes according to the volume ratio of 1: 1 by magnetic bead buffer solution, obtains magnetic separation agent in kit of the present invention; Described magnetic bead buffer solution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
Embodiment 2
One, the preparation process of enzyme labelled antibody:
1,2.5mg glycosylated hemoglobin monoclonal antibody is dissolved in the N of 1.0ml, in dinethylformamide, add 10mg/ml horseradish peroxidase aqueous solution and the 1.3mg carbodiimides of 1ml, after 1 hour, the carbodiimides of 1.0ml 20mg/ml is added, potpourri constantly stirs, and 4 ℃ are spent the night;
2, the solution of step 1 is packed in bag filter, to the PH7.4PBS dialysis of 0.15M, 4 ℃ are spent the night, and collect and retain liquid; Then adding 10ml concentration is the BSA solution of 15mg/ml, and 4 ℃ store for future use; Finally the horseradish peroxidase of collecting is mixed with the volume ratio of 1: 1000 with enzyme labelled antibody dilution with the conjugate of glycosylated hemoglobin monoclonal antibody, obtain enzyme labelled antibody; Described enzyme labelled antibody dilution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
Embodiment 3
Reinforcing agent preparation steps:
1, take TRIS1.56g and NaCl 4.23g in 1L container; With pipettor by Proclin-300 measure 0.2ml in the beaker of 10ml purified water completely dissolve after, pour in above-mentioned 1L container;
2, measure 800ml purified water in above-mentioned 1L container with graduated cylinder, fully stir, adjust PH until dissolve completely, control PH between 7.35-7.45;
3, take Mak330.9g in above-mentioned 1L container; Last constant volume 1000ml, after dissolving completely, with the filtration of 0.2um filter.Mak33 is the commercial reagent of Roche Holding Ag.
Embodiment 4
The preparation steps of calibration object and the product of control:
1, peak: maximum concentration point is X, impact point concentration is A, B, C, D, E, F, while preparing the solution of V volume, need add the volume of raw material for being respectively:
| Concentration | Add calibration object dilution volume | Add X volume |
| A | V-A*V/X | A*V/X |
| B | V-B*V/X | B*V/X |
| C | V-C*V/X | C*V/X |
| D | V-D*V/X | D*V/X |
| E | V-E*V/X | E*V/X |
| F | V-F*V/X | F*V/X |
2,, in glycosylated hemoglobin (glycosylated hemoglobin) immue quantitative detection reagent box, glycosylated hemoglobin antigen calibration object raw material (being purchased from Santa Cruz company) is mixed with by purified water that concentration point is 50,100,200,400,800ng/ml; Control product with the concentration point of purified water preparation be 100,400ng/ml.
3, after dissolving completely, post label in 2-8 ℃ of refrigeration house storage, the term of validity is 12 months.
Embodiment 5:
Concentrate preparation steps:
1, take TRIS 12.54g and NaCl 325.6g in 1L container;
2, after taking 5g Tween-20 and adding suitable quantity of water in 100ml container it is dissolved completely, pour in said vesse;
3, with pipettor by Proclin-300 measure 0.2ml in the beaker that fills 10ml purified water completely dissolve after, pour in above-mentioned 1L container;
4, measure 800ml purified water in above-mentioned 1L container with graduated cylinder, fully stir, until dissolve completely;
5, adjust PH with HCL or NaOH, measure its scope between 7.35-7.45;
6, last constant volume 1000ml, surveys pH value, and scope meets the requirements between 7.35-7.45, after dissolving completely, filters with 0.2um filter; After having filtered, post label in 2-8 ℃ of refrigeration house storage, the term of validity is 12 months;
Embodiment 6
Substrate formulation operations step:
1, take TRIS 2.35g, NaCl 6.41g, Na
2sO
30.002g and Proclin-3000.2ml are in 1L beaker;
2, measure 600ml purified water in 1L beaker with graduated cylinder, fully stir, until dissolve completely; With HCl or NaOH tune PH, measure its scope between 7.95-8.05;
3, add after 250ml Lumi-Phos 530, filter and collect filtrate with 0.2um filter, be settled to 1000ml by purified water, after mixing, post label in 2-8 ℃ of refrigeration house storage, the term of validity is 12 months.
The using method of Case monitoring management system of the present invention is as follows:
1, adopt blood sampling device to get blood to patient and obtain detection sample;
2, add 15 μ l glycosylated hemoglobin calibration objects, control product, detect sample to corresponding test tube bottom;
3, add 30 μ l enzyme labelled antibodies, 30 μ l reinforcing agents and 30 μ l magnetic separation agents to each test tube;
4, cover test tube with plastic sheeting, multitube vortex mixer after tube shaken frame 30s, is put 37 ℃ of water-baths 30 minutes gently.
5, test tube frame linking is put to magnetic separator, guarantees that every test tube all contacts with separator surface, precipitates 2 minutes, and the separation vessel that then reverses is slowly poured out supernatant.
6, concentrate is with after 20 times of purified water dilutions, adds concentrate after 200 μ l dilutions to each test tube, puts on multitube vortex mixer vibration gently and mixes 30s.When application of sample, should avoid application of sample dynamics excessive and cause magnetic bead to spill.Mix and want thoroughly.
7, add 200 μ l substrates and mix 3 seconds to test tube, detect with ready luminous detector rapidly.
Clinical testing:
Case: type ii diabetes patient 90 examples of the People's Hospital of city clinical definite, male 59 examples, female's 31 examples.Wherein, patient's fasting blood-glucose FPG >=7.0mmol/L, is defined as on an empty stomach empty calory at least 8 hours and takes in; 2h blood sugar >=11.1mmol/L when oral glucose tolerance test.
Testing result: as follows by the detection that utilizes type ii diabetes clinical case management system for monitoring provided by the invention to carry out glycosylated hemoglobin to above-mentioned 90 routine patients:
Can determine patient's administering mode according to above-mentioned saccharification hemoglobin content ,≤6.5% patient can temporarily not take any medicine, adopts diet control, and check in each week once; >=6.5% and≤8.5% patient can adopt diet and oral antidiabetic drug to control, check is once week about; >=8.5% patient advises adopting the scheme of insulin injection treatment.It should be noted that physiological condition singularity and the otherness individual according to some, above-mentioned administering mode might not be suitable for all patients.
Although above the present invention is described in detail with a general description of the specific embodiments, on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (1)
1. a type ii diabetes clinical case management system for monitoring, is characterized in that, described management system for monitoring comprises blood sampling device and glycosylated hemoglobin pick-up unit; Described blood sampling device is venous detaining needle or blood collecting pen; Described glycosylated hemoglobin pick-up unit is glycosylated hemoglobin detection kit, and described kit comprises glycosylated hemoglobin magnetic separation agent, enzyme labelled antibody, reinforcing agent, calibration object, control product, concentrate and substrate;
Described kit is prepared in accordance with the following steps:
The first step: the preparation process of magnetic separation agent:
1) 1.0mg disuccinimidyl suberate is dissolved in 50 μ LDMSO, get in the 0.1mol/L PB damping fluid that the anti-glycosylated hemoglobin monoclonal antibody of 2mg is dissolved in pH9.5 to cumulative volume be 1mL;
2) join step 1 with the disuccinimidyl suberate that liquid-transfering gun is drawn in step 1) antibody-solutions in, put room temperature 90min;
3) by step 2) solution that obtains join in concentration tube, then put in high speed freezing centrifuge under 3000g concentrated 30min to volume be 0.5mL;
4) get 0.5mL magnetic bead, add in 5mL reaction cup, put into test tube rack, after 2 minutes, draw supernatant through magnet adsorption;
5) add step 3) obtain solution in above-mentioned magnetic bead, mix rear room temperature reaction 4 hours;
6) add 37 ℃ of the Tris solution 15 minutes of 0.3mL1mol/L;
7) add the PB of 1.5mL pH7.20.1mol/L to clean the magnetic bead of mark, mix 30 seconds, added, remove supernatant;
8) preserve liquid with 100mL magnetic bead magnetic bead is proceeded to 125mL vial; It is 0.1%BSA that magnetic bead is preserved formula of liquid, 0.05%Tween-20,0.02%NaN
3, 20% ethanol;
9) by step 8) obtain solution mix according to the volume ratio of 1: 1 by magnetic bead buffer solution, obtain magnetic separation agent; Described magnetic bead buffer solution is that concentration is the Tris-HCl damping fluid of 1mol/L;
Second step: enzyme labelled antibody preparation process:
1) 2.5mg glycosylated hemoglobin monoclonal antibody is dissolved in the N of 1.0mL, in dinethylformamide, add 10mg/mL horseradish peroxidase aqueous solution and the 1.3mg carbodiimides of 1mL, after 1 hour, the carbodiimides of 1.0ml20mg/mL is added, potpourri constantly stirs, and 4 ℃ are spent the night;
2) by step 1) solution pack in bag filter, to the pH7.4PBS dialysis of 0.15M, 4 ℃ are spent the night, and collect and retain liquid; Then adding 10mL concentration is the BSA solution of 15mg/mL, and 4 ℃ store for future use; Finally above-mentioned solution is mixed with the volume ratio of 1: 1000 with enzyme labelled antibody dilution, obtain enzyme labelled antibody; Described enzyme labelled antibody dilution is that concentration is the Tris-HCl damping fluid of 1mol/L;
The 3rd step: reinforcing agent preparation steps:
1) take Tris1.56g and NaCl4.23g in 1L container; With pipettor by Proclin-300 measure 0.2mL in the beaker of 10mL purified water completely dissolve after, pour in above-mentioned 1L container;
2) measure 800mL purified water in above-mentioned 1L container with graduated cylinder, fully stir, until dissolve completely, adjust pH between 7.35-7.45;
3) take Mak330.9g in above-mentioned 1L container; Last constant volume 1000mL, after dissolving completely, with 0.2 μ m filter filtration; The 4th step:
The preparation of calibration object and the product of control:
Glycosylated hemoglobin antigen is made into concentration is respectively 50,100,200,400, the calibration object of 800ng/mL; Glycosylated hemoglobin antigen is made into concentration is respectively 100, the control product of 400ng/mL;
The 5th step:
Concentrate preparation steps, preparation 1L:
1) take Tris12.54g and NaCl325.6g in 1L container;
2) after taking 5g Tween-20 and adding 20mL water in 100mL container it is dissolved completely, pour in above-mentioned 1L container;
3) with pipettor by Proclin-300 measure 0.2mL in the beaker that fills 10mL purified water completely dissolve after, pour in above-mentioned 1L container;
4) measure 800mL purified water in above-mentioned 1L container with graduated cylinder, fully stir, until dissolve completely;
5) adjust pH, control its scope between 7.35-7.45;
6) last constant volume 1000mL, filters and get final product with 0.2 μ m filter after dissolving completely.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110399730.XA CN102495217B (en) | 2011-12-06 | 2011-12-06 | Clinical case monitoring and managing system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110399730.XA CN102495217B (en) | 2011-12-06 | 2011-12-06 | Clinical case monitoring and managing system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102495217A CN102495217A (en) | 2012-06-13 |
| CN102495217B true CN102495217B (en) | 2014-06-25 |
Family
ID=46187058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110399730.XA Expired - Fee Related CN102495217B (en) | 2011-12-06 | 2011-12-06 | Clinical case monitoring and managing system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102495217B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104897589B (en) * | 2015-06-02 | 2017-05-31 | 中国农业科学院兰州畜牧与兽药研究所 | A kind of qualitative assessment medicine hemolytic refers to calibration method |
| CN108226481A (en) * | 2018-01-08 | 2018-06-29 | 宁波紫园医疗器械有限公司 | A kind of magnetic bead reagent for chemiluminescence immunoassay detection reagent |
| CN110070910B (en) * | 2019-04-26 | 2023-04-18 | 复旦大学附属华山医院 | Hemangioblastoma patient typing management system |
| CN110575184B (en) * | 2019-09-24 | 2021-12-03 | 江苏科华医疗器械科技有限公司 | Stepless regulation type range blood sampling device |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101802620A (en) * | 2007-02-22 | 2010-08-11 | 特提斯生物科学公司 | Metabolic markers of diabetic conditions and methods of use thereof |
| JP2010187604A (en) * | 2009-02-19 | 2010-09-02 | Sekisui Medical Co Ltd | Method for measuring sample for measuring glycosylated hemoglobin |
| CN101915849A (en) * | 2010-06-30 | 2010-12-15 | 深圳市国赛生物技术有限公司 | Method for measuring glycosylated hemoglobin content |
| JP2011105609A (en) * | 2009-11-13 | 2011-06-02 | Sanofi-Aventis Deutschland Gmbh | Method for treating type-2 diabetes including add-on therapy to metformin |
| CN201886026U (en) * | 2010-12-10 | 2011-06-29 | 四川迈克生物科技股份有限公司 | Test paper tape for quick quantitative detection of glycated hemoglobin by immunochromatography |
-
2011
- 2011-12-06 CN CN201110399730.XA patent/CN102495217B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101802620A (en) * | 2007-02-22 | 2010-08-11 | 特提斯生物科学公司 | Metabolic markers of diabetic conditions and methods of use thereof |
| JP2010187604A (en) * | 2009-02-19 | 2010-09-02 | Sekisui Medical Co Ltd | Method for measuring sample for measuring glycosylated hemoglobin |
| JP2011105609A (en) * | 2009-11-13 | 2011-06-02 | Sanofi-Aventis Deutschland Gmbh | Method for treating type-2 diabetes including add-on therapy to metformin |
| CN101915849A (en) * | 2010-06-30 | 2010-12-15 | 深圳市国赛生物技术有限公司 | Method for measuring glycosylated hemoglobin content |
| CN201886026U (en) * | 2010-12-10 | 2011-06-29 | 四川迈克生物科技股份有限公司 | Test paper tape for quick quantitative detection of glycated hemoglobin by immunochromatography |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102495217A (en) | 2012-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baker et al. | Haemolytic-uraemic syndrome in typhoid fever | |
| CN102495217B (en) | Clinical case monitoring and managing system | |
| Bjorkholm et al. | A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol | |
| CN106727700A (en) | Prepare the method for platelet rich plasma PRP and the purposes of the platelet rich plasma | |
| Havey et al. | Case report: recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin | |
| Guo et al. | Long term safety and immunological effects of a nanobiotherapeutic, bovine poly-[hemoglobin-catalase-superoxide dismutase-carbonic anhydrase], after four weekly 5% blood volume top-loading followed by a challenge of 30% exchange transfusion | |
| SU1767433A1 (en) | Method of determining insulin resistance of immunogenesis in patients with type 1 diabetes mellitus | |
| Jahagirdar et al. | Management of diabetic ketoacidosis in PICU | |
| Shah et al. | 366 The Not So Insignificant Anti-A1 Antibody: Cause of Severe Hemolytic Transfusion Reaction | |
| Krish et al. | The Case∣ Hyperbicarbonatemia in a patient with Waldenstrom's macroglobulinemia | |
| INWOOD et al. | Anti-A hemolytic transfusion with packed O cells | |
| CN102435754A (en) | Quantitative determination kit for free triiodothyronine (FT3) and detection method thereof | |
| Alizadeh et al. | Loss of consciousness in a little traveler | |
| Dale | Preanalytic variables in laboratory testing | |
| Lockhart et al. | 367 Red Blood Cell Exchange for Treatment of Acquired Methemoglobinemia in a Hospitalized Patient: A Case Report | |
| CN100546585C (en) | Compound puerarin injection and preparation method thereof | |
| CN103356478A (en) | Ibuprofen injection composition and preparation method thereof | |
| Ando et al. | Reduced capacity of mononuclear cells to synthesize cytokines against an inflammatory stimulus in uremic patients | |
| Giammancoab et al. | A lesson from a fatal case of leptospirosis | |
| Sun et al. | Comparative analysis of different drug delivery methods of injectable hydrogel nanomaterials of insulin biomaterials via multiple daily injections and continuous subcutaneous insulin infusion in the treatment of type 1 diabetes mellitus in children | |
| CN105616347A (en) | Medicinal composition containing ibuprofen and preparation method of medicinal composition | |
| Sultan et al. | Dysmagenesemia in critically ill patients: prevalence and nature of magnesium disorder. | |
| AL-Ghanimi | Supervised | |
| Ekladious | Hypoglycaemia due to Autoimmunity | |
| Gobina et al. | POS-023 ACUTE KIDNEY INJURY WITH NON-CYSTIC, NON-OBSTRUCTIVE NEPHROMEGALY: CLINICAL PRESENTATION AND OUTCOMES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xie Wenru Inventor after: Du Qing Inventor before: Xie Wenru |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: XIE WENRU TO: XIE WENRU DU QING |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HUANG CHUANFENG Free format text: FORMER OWNER: XIE WENRU Effective date: 20140421 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Huang Chuanfeng Inventor after: Guo Yongcheng Inventor before: Xie Wenru Inventor before: Du Qing |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: XIE WENRU DU QING TO: HUANG CHUANFENG GUO YONGCHENG Free format text: CORRECT: ADDRESS; FROM: 276005 LINYI, SHANDONG PROVINCE TO: 276300 LINYI, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140421 Address after: 276300 Yinan County People's Hospital, Yuquanlu Road 70, Yinan County, Shandong, Linyi Applicant after: Huang Chuanfeng Address before: 276005 medical section of Linyi mental health center, No. ten 119 street, Lanshan District, Shandong, Linyi Applicant before: Xie Wenru |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zheng Min Inventor before: Huang Chuanfeng Inventor before: Guo Yongcheng |
|
| COR | Change of bibliographic data | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160121 Address after: 518100 Guangdong city of Shenzhen province Baoan District Shiyan Street paddy village fourth industrial zone wish Dragon Road No. 50 Sailian Industrial Park A, B building, B building four floor A Patentee after: SHENZHEN CHENGDA HENGTAI TECHNOLOGY CO.,LTD. Address before: 276300 Yinan County People's Hospital, Yuquanlu Road 70, Yinan County, Shandong, Linyi Patentee before: Huang Chuanfeng |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190705 Address after: 518101 Paddy Field Community, Shiyan Street, Baoan District, Shenzhen City, Guangdong Province Patentee after: Shenzhen Huachuang Technology Co.,Ltd. Address before: 518100 Paddy Field Community, Shiyan Street, Baoan District, Shenzhen City, Guangdong Province Patentee before: SHENZHEN CHENGDA HENGTAI TECHNOLOGY CO.,LTD. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140625 Termination date: 20211206 |